Anika Therapeutics | ANIK - Current Liabilities


Anika Therapeutics reported $22.15M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Abbott USD 16.15B 1.66B Sep/2026
Agenus USD 231.82M 17.42M Jun/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Insmed USD 596.57M 157.83M Sep/2026
Integra LifeSciences USD 329M 1.88M Sep/2026
Intrexon USD 23.02M 38K Jun/2024
J&J USD 55.46B 562M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merit Medical Systems USD 265.08M 150K Sep/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 29.77B 2.16B Sep/2026
Smith & Nephew USD 2.05B 510M Jun/2026
Stryker USD 6.5B 184M Sep/2026
Veracyte USD 84.21M 21.47M Sep/2026
Xencor USD 76.27M 5.6M Sep/2026
Zimmer Biomet Holdings USD 3.5B 488.9M Sep/2026